Julie Grant

Julie Grant is a distinguished healthcare investor and company builder affiliated with Canaan Partners.

She holds an MBA from Stanford University Graduate School of Business, along with a background in Biochemistry and Molecular Biophysics from Yale University and additional studies at the University of Cambridge.

Julie Grant's notable roles include being the Co-Founder and CEO at Day One Biopharmaceuticals, chair of the Board of Directors at the same organization, and a former General Partner at Canaan Partners.

Her extensive experience in the healthcare sector encompasses diverse positions such as serving on the boards of Synthekine, Nocion Therapeutics, Inc., Biden Cancer Initiative, Protagonist Therapeutics, Glooko, Chrono Therapeutics, Cellular Research, Cytomx Therapeutics, Aldea Pharma, Dermira, Inc., and Labrys Biologics, Inc.

Julie has also been involved in various capacities at Canaan Partners, including as a Partner, Principal, and Associate. She has held key roles at Genentech, contributing to projects like Biooncology New Products, Tarceva, and business development.

Before her illustrious career in the healthcare industry, Julie Grant gained valuable experience through internships at Genentech and Yale University Careers. She also served as a Summer Analyst at Goldman Sachs.